218457-67-1
CB-103
CAS: 218457-67-1
Molecular Formula: C15H18N2O
218457-67-1 - Names and Identifiers
218457-67-1 - Physico-chemical Properties
| Molecular Formula | C15H18N2O |
| Molar Mass | 242.32 |
| Melting Point | 89-90 |
| Solubility | DMSO: 250 mg/mL (1031.69 mM), Need ultrasonic( < 1 mg/ml refers to the product slightly soluble or insoluble) |
| Appearance | solid |
| Color | Off-white to pale orange |
| Storage Condition | 2-8°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Use | CB-103 is a pioneering, orally active notch signaling pathway inhibitor with anti-tumor activity. For details, please refer to the patent literature US9296682B2. |
218457-67-1 - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Hazard Note | Irritant |
218457-67-1 - Reference
| Reference Show more | 1. Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.2. R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.3. Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway. |
218457-67-1 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.127 ml | 20.634 ml | 41.268 ml |
| 5 mM | 0.825 ml | 4.127 ml | 8.254 ml |
| 10 mM | 0.413 ml | 2.063 ml | 4.127 ml |
| 5 mM | 0.083 ml | 0.413 ml | 0.825 ml |
Last Update：2024-01-02 23:10:35
218457-67-1 - Reference Information
| biological activity | CB-103 is an orally active inhibitor of the Notch transcriptional activation complex. CB-103 produces a loss-of-Notch phenotype in Drosophila and mice and inhibits the growth of human breast cancer and leukemia xenografts. |
| Target | Value |
| Cell Line: | RPMI 8402, KOPTK1, PANC1, nRas driven melanoma cells |
| Concentration: | 10 μM |
| Incubation Time: | 4 days, 6 days |
| Result: | Caused a significant reduction in their growth potential. Inhibited growth of GSI/Mab resistant triple negative breast cancer. |
| Animal Model: | NSG mice, triple negative breast cancer mouse xenograft model |
| Dosage: | 25 mg/kg |
| Administration: | Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks |
Last Update：2024-04-09 15:16:57
Supplier List
Product Name: CB-103 Visit Supplier Webpage Request for quotation
CAS: 218457-67-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 218457-67-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: CB-103 Visit Supplier Webpage Request for quotation
CAS: 218457-67-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 218457-67-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History